Rekombinanter TNFSF11 (Denosumab Biosimilar) Antikörper

Produktnummer ABIN7200656

Produktdetails anti-TNFSF11 (Denosumab Biosimilar) Antikörper

Target: TNFSF11 (Denosumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser TNFSF11 (Denosumab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Verwendungszweck: Denosumab Biosimilar, Human RANKL Monoclonal Antibody

Spezifität: The monoclonal antibody denosumab biosimilar specifically binds to the human RANKL (RANK ligand) protein.

Produktmerkmale: Recombinant Humanized IgG2 Monoclonal Antibody.

Aufreinigung: Protein A affinity column

Reinheit: > 95% by SDS-PAGE under reducing conditions and HPLC.

Sterilität: 0.2 μm filtered

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method.

Immunogen: The monoclonal antibody denosumab biosimilar was produced in the denosumab biosimilar CHO stable cell line.

Isotyp: IgG2 kappa

Anwendungsinformationen

Applikationshinweise: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by denosumab.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Konservierungsmittel: Without preservative

Handhabung: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Lagerung: -20 °C

Informationen zur Lagerung: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Haltbarkeit: 12 months

Details zu TNFSF11 (Denosumab Biosimilar)

Target: TNFSF11 (Denosumab Biosimilar)

Abstract: TNFSF11 (Denosumab Biosimilar) Produkte

Synonyme: CD254 antikoerper, ODF antikoerper, OPGL antikoerper, OPTB2 antikoerper, RANKL antikoerper, TRANCE antikoerper, hRANKL2 antikoerper, sOdf antikoerper, TNF superfamily member 11 antikoerper, TNFSF11 antikoerper

Substanzklasse: Biosimilar

Hintergrund: Denosumab, a fully human monoclonal antibody, inhibits the RANKL (RANK ligand) protein, the primary signal for bone removal. Denosumab can be used for the treatment of osteoporosis, treatment-induced bone loss, bone metastases, multiple myeloma, and giant cell tumor of bone.